Early Intervention Can Halt Heart Damage
Posted on: Tuesday, 28 August 2007, 12:16 CDT
U.S. researchers found treating people before they have cardiovascular abnormalities but show no symptoms can slow progression or reverse heart disease.
University of Minnesota researchers performed a double-blind study of 76 asymptomatic subjects with early markers for cardiovascular disease, based on the 10-factor Rasmussen Disease Score. The 10 tests in the Rasmussen Disease Score include: large and small artery elasticity; resting and treadmill exercise blood pressure; carotid artery initial-media thickness; retinal vascular photography; micro-albuminuria; electrocardiography; echocardiography; and plasma B-type natriuretic peptide blood levels.
During the first six months of the study, 38 subjects received a placebo and the other 38 subjects took 160 mg of Valsartan, a drug that blocks a hormone that is detrimental to the blood vessels and the heart. During the next six months, both groups took Valsartan.
The study participants who took the drug for the first six months significantly reduced their Rasmussen Disease Score compared with those who took the placebo. At the 12-month mark -- all took the drug -- every patient showed better Rasmussen Disease Scores, effectively demonstrating that Valsartan can slow progression and even reverse early cardiovascular disease in asymptomatic high-risk patients, reported the study published in the Journal of American College of Cardiology.
Source: United Press International
Related Articles
- Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
- AstraZeneca Granted Six-Month Pediatric Exclusivity for Prostate Cancer Drug
- Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program
- Olanzapine Long-Acting Injection (LAI) Shown to Maintain Treatment Benefit in Schizophrenia for Up to Six Months
- AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (Anastrozole) From the FDA
- New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
- Vernalis Plc: Interim Results for the Six Months Ended 30 June 2006
- Roche Study Shows Hepatitis C Patients Need Six Months of Treatment
- LUNESTA(TM) Second Six-Month Study Results Presented at American Neurological Association Annual Meeting
- LUNESTA(TM) Second Six-Month Study Data Confirms Findings of First Six-Month Study
 |
 |
User Comments (0)
RSS Feeds